Critically, AML blasts isolated from HLA-A*0201+ AML patients treated with decitabine sufficiently stimulated HLA-A*0201-restricted NY-ESO-1-specific CTL responses as shown by increased levels of intracellular cytokines in HLA-A*0201/NY-ESO-1157-165 tetramer+ CD8+ T cells (60). This evidence concerns the gene CD8A and acute myeloid leukemia.